How to participate?

Clinician

WHY SHOULD YOU COLLABORATE?

  • Free research grade Molecular reports will be generated for your contributed patients and will be sent to you within 6 weeks after patient eligibility is confirmed. These reports will contain clinically actionable molecular alterations.

  • Molecular tumor boards are in place depending on the tumour in order to discuss about best strategy for your patient.

  • Access to all broad profiling data (raw and processed data) from your patients.

  • The patient eligible for IMMUcan will be compensated 250 euros at baseline, and up to 2500 euros for some progression specimen (metastatic patients).

  • All costs for HBM shipment and analyses are covered by IMMUcan.

  • Possibility of authorship on publications (e.g. as part of a scientific collaboration).

HOW TO COLLABORATE?

We are looking for investigators interested in recruiting cancer patients in the indications of interest for IMMUcan.

Patients will be recruited via SPECTA, the integrated research infrastructure under EORTC legal sponsorship. Once you become an authorized investigator within the platform, you will be able to recruit patients in all opened cohorts, including the IMMUcan’s ones.

Check here for more information about SPECTA.

Information on IMMUcan cohorts and patients’ eligibility criteria can be found from the SPECTA website.

SPECTA Infrastructure

Are you a principle investigator, interested to join SPECTA?

Join SPECTA

Study sponsor

WHY SHOULD YOU COLLABORATE?

  • Access at no cost to the read outs of the molecular and immunoprofiling tests performed on your patients (raw and analysed data).

  • Opportunities to engage in IMMUcan scientific activities including possibility to publish.

  • Broad translational research performed on your study samples, helping you with identification of biomarkers of response to treatment.

Benefits for the collaborators

HOW TO COLLABORATE?

CHECK THE REQUIREMENTS FOR CLINICAL STUDY TO BE ELIGIBLE FOR IMMUcan

01

Academically sponsored study

Existing contractual obligation should not prevent the use of patient material for IMMUcan.

02

Adequate Patient
Informed Consent

It should authorize the use of patient material in collaboration with industry.

03

Clinical data availability

Clinical outcomes data should be available for IMMUcan not later than end of 2021.

Join Us

Researcher

WHY SHOULD YOU COLLABORATE?

  • Access to high quality molecular and clinical datasets for biomarker and treatment strategy research (data sharing).

  • Opportunities to propose innovative analysis of IMMUcan left over biological material (sample and data sharing).

  • Material and clinical data are clinical trial grade (longitudinal follow up, quality controlled processes for data and sample collection and processing).

HOW TO COLLABORATE?

Please check here the IMMUcan policy for access to data and Human Biological material.

Researcher - Illustration

INTERESTED TO COLLABORATE?

Please use the contact form. We will review your proposal and come back to you.

Access to IMMUcan data and biological material

Please consult IMMUcan policy

Read More